The Renaissance of Complement Therapeutics

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2017 Dec 5

PMID 29199277

Citations 187

Authors

Daniel Ricklin

Dimitrios C Mastellos

Edimara S Reis

John D Lambris

Affiliations

Soon will be listed here.

Abstract

The increasing number of clinical conditions that involve a pathological contribution from the complement system - many of which affect the kidneys - has spurred a regained interest in therapeutic options to modulate this host defence pathway. Molecular insight, technological advances, and the first decade of clinical experience with the complement-specific drug eculizumab, have contributed to a growing confidence in therapeutic complement inhibition. More than 20 candidate drugs that target various stages of the complement cascade are currently being evaluated in clinical trials, and additional agents are in preclinical development. Such diversity is clearly needed in view of the complex and distinct involvement of complement in a wide range of clinical conditions, including rare kidney disorders, transplant rejection and haemodialysis-induced inflammation. The existing drugs cannot be applied to all complement-driven diseases, and each indication has to be assessed individually. Alongside considerations concerning optimal points of intervention and economic factors, patient stratification will become essential to identify the best complement-specific therapy for each individual patient. This Review provides an overview of the therapeutic concepts, targets and candidate drugs, summarizes insights from clinical trials, and reflects on existing challenges for the development of complement therapeutics for kidney diseases and beyond.

Citing Articles

Unravelling the complexity of CARPA: a review of emerging advancements in therapeutic strategies.

Saxena S, Sharma S, Kumar G, Thakur S Arch Dermatol Res. 2025; 317(1):439.

PMID: 39971823 DOI: 10.1007/s00403-025-03971-z.

Pegcetacoplan for the Treatment of Paediatric C3 Glomerulonephritis: A Case Report.

Guzman G, Perry K Nephrology (Carlton). 2025; 30(2):e70001.

PMID: 39871447 PMC: 11772912. DOI: 10.1111/nep.70001.

Exploring Potential Complement Modulation Strategies for Ischemia-Reperfusion Injury in Kidney Transplantation.

Troise D, Allegra C, Cirolla L, Mercuri S, Infante B, Castellano G Antioxidants (Basel). 2025; 14(1).

PMID: 39857400 PMC: 11761266. DOI: 10.3390/antiox14010066.

Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring.

Gadeberg T, Jorgensen M, Olesen H, Lorentzen J, Harwood S, Almeida A Nat Struct Mol Biol. 2025; .

PMID: 39849196 DOI: 10.1038/s41594-024-01467-4.

Complement-targeted therapeutics: Are we there yet, or just getting started?.

Ricklin D Eur J Immunol. 2024; 54(12):e2350816.

PMID: 39263829 PMC: 11628912. DOI: 10.1002/eji.202350816.

References

Audemard-Verger A, Descloux E, Ponard D, Deroux A, Fantin B, Fieschi C . Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients. Medicine (Baltimore). 2016; 95(19):e3548. PMC: 4902496. DOI: 10.1097/MD.0000000000003548. View

Morgan B, Harris C . Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015; 14(12):857-77. PMC: 7098197. DOI: 10.1038/nrd4657. View

Patzelt J, Verschoor A, Langer H . Platelets and the complement cascade in atherosclerosis. Front Physiol. 2015; 6:49. PMC: 4345806. DOI: 10.3389/fphys.2015.00049. View

Bomback A, Smith R, Barile G, Zhang Y, Heher E, Herlitz L . Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012; 7(5):748-56. PMC: 3338285. DOI: 10.2215/CJN.12901211. View

Phieler J, Garcia-Martin R, Lambris J, Chavakis T . The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol. 2013; 25(1):47-53. PMC: 3734549. DOI: 10.1016/j.smim.2013.04.003. View

Finch A, Wong A, Paczkowski N, Wadi S, Craik D, Fairlie D . Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem. 1999; 42(11):1965-74. DOI: 10.1021/jm9806594. View

Chen M, Jayne D, Zhao M . Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017; 13(6):359-367. DOI: 10.1038/nrneph.2017.37. View

Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D . Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017; 37(8):1249-1255. DOI: 10.1007/s00296-017-3686-5. View

Nester C, Smith R . Complement inhibition in C3 glomerulopathy. Semin Immunol. 2016; 28(3):241-9. DOI: 10.1016/j.smim.2016.06.002. View

10.

Harder M, Kuhn N, Schrezenmeier H, Hochsmann B, von Zabern I, Weinstock C . Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2016; 129(8):970-980. PMC: 5324716. DOI: 10.1182/blood-2016-08-732800. View

11.

Rinder C, Rinder H, Smith B, Fitch J, Smith M, Tracey J . Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995; 96(3):1564-72. PMC: 185782. DOI: 10.1172/JCI118195. View

12.

Risitano A, Notaro R, Pascariello C, Sica M, Del Vecchio L, Horvath C . The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012; 119(26):6307-16. DOI: 10.1182/blood-2011-12-398792. View

13.

Dobo J, Szakacs D, Oroszlan G, Kortvely E, Kiss B, Boros E . MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep. 2016; 6:31877. PMC: 4989169. DOI: 10.1038/srep31877. View

14.

Thurman J . Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2014; 65(1):156-68. PMC: 4272665. DOI: 10.1053/j.ajkd.2014.06.035. View

15.

Stegall M, Chedid M, Cornell L . The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol. 2012; 8(11):670-8. DOI: 10.1038/nrneph.2012.212. View

16.

Martin M, Blom A . Complement in removal of the dead - balancing inflammation. Immunol Rev. 2016; 274(1):218-232. DOI: 10.1111/imr.12462. View

17.

Gros P, Milder F, Janssen B . Complement driven by conformational changes. Nat Rev Immunol. 2007; 8(1):48-58. DOI: 10.1038/nri2231. View

18.

Gewurz A, Imherr S, Strauss S, Gewurz H, Mold C . C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol. 1983; 54(1):253-8. PMC: 1536206. View

19.

Fujita T . Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol. 2002; 2(5):346-53. DOI: 10.1038/nri800. View

20.

Zhang Y, Shao D, Ricklin D, Hilkin B, Nester C, Lambris J . Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology. 2015; 220(8):993-8. PMC: 4510458. DOI: 10.1016/j.imbio.2015.04.001. View